Plasma-based testing seems to have several advantages over tumor tissue biopsy; firstly, it reduces medical costs, risk of complications related to invasive procedures, and TATs; moreover, the analysis of mutations in genes, such as EGFR, ALK, ROS1, and BRAF safer with this method, compared to tissue biopsy. This evidence concerns the gene EGFR and neoplasm.